Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

NCT05654701 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Hypoparathyroidism

Interventions

DRUG: Palopegteriparatide (TransCon PTH)

Sponsor

Ascendis Pharma Bone Diseases A/S